This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
Newly developed method helps to quantify the residual immunogenic potential of decellularized human heart valves
Dot-blot techniques demonstrate highly individual immune response towards decellularized homografts - Results published Open Access in the European Journal of Cardio-Thoracic-Surgery
Presentation of the early ARISE results at the 2019 Meeting of the European Association for Cardio-Thoracic-Surgery (EACTS) Saturday 5th of October in Lisbon, Portugal
Results for pediatric aortic valve replacement using cell-free homografts will be presented as well at the EACTS 2019 [more]
Early results of the ESPOIR Trial published in 2019
The publication of the early ESPOIR Trial and the midterm ESPOIR Registry results has been cited more than 20 times since 2019 and lists upon the most cited publications within the European Journal of Cardio-Thoracic-Surgery... [more]
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.